

Sarah Shigdar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1477973/publications.pdf>

Version: 2024-02-01

59
papers

3,073
citations

172457

29
h-index

155660

55
g-index

60
all docs

60
docs citations

60
times ranked

4952
citing authors

#	ARTICLE	IF	CITATIONS
1	Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer. <i>Pharmacological Research</i> , 2022, 175, 106019.	7.1	20
2	Triple-negative breast cancer brain metastasis: An update on druggable targets, current clinical trials, and future treatment options. <i>Drug Discovery Today</i> , 2022, 27, 1298-1314.	6.4	10
3	Modelling of mass transport and distribution of aptamer in blood-brain barrier for tumour therapy and cancer treatment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 173, 121-131.	4.3	5
4	Profiling Cancer Cells by Cell-SELEX: Use of Aptamers for Discovery of Actionable Biomarkers and Therapeutic Applications Thereof. <i>Pharmaceutics</i> , 2022, 14, 28.	4.5	17
5	Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6163.	4.1	12
6	Aptamers: Cutting edge of cancer therapies. <i>Molecular Therapy</i> , 2021, 29, 2396-2411.	8.2	52
7	Novel Detection of Nasty Bugs, Prevention Is Better than Cure. <i>International Journal of Molecular Sciences</i> , 2021, 22, 149.	4.1	7
8	Efficacy of promising flavonoids from <i>Festuca</i> , <i>Lonicera</i> , and <i>Acacia</i> genera against glioblastoma multiforme; potential for the Dandenong Ranges. , 2020, , 383-422.		1
9	Bifunctional Aptamer–Doxorubicin Conjugate Crosses the Blood–Brain Barrier and Selectively Delivers Its Payload to EpCAM-Positive Tumor Cells. <i>Nucleic Acid Therapeutics</i> , 2020, 30, 117-128.	3.6	41
10	Antibodies, Nanobodies, or Aptamers—Which Is Best for Deciphering the Proteomes of Non-Model Species?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2485.	4.1	22
11	Anything You Can Do, I Can Do Better: Can Aptamers Replace Antibodies in Clinical Diagnostic Applications?. <i>Molecules</i> , 2019, 24, 4377.	3.8	65
12	Radiolabelled Aptamers for Theranostic Treatment of Cancer. <i>Pharmaceutics</i> , 2019, 12, 2.	3.8	15
13	Aptamer-Based Diagnostics and Therapeutics. <i>Pharmaceutics</i> , 2019, 12, 6.	3.8	6
14	Mesoporous silica nanorods toward efficient loading and intracellular delivery of siRNA. <i>Journal of Nanoparticle Research</i> , 2018, 20, 1.	1.9	10
15	Aptamers as potential therapeutic agents for ovarian cancer. <i>Biochimie</i> , 2018, 145, 34-44.	2.6	17
16	EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs. <i>Cancers</i> , 2018, 10, 19.	3.7	46
17	Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis. <i>Mini-Reviews in Medicinal Chemistry</i> , 2018, 18, 976-989.	2.4	8
18	Challenges and opportunities for siRNA-based cancer treatment. <i>Cancer Letters</i> , 2017, 387, 77-83.	7.2	82

#	ARTICLE	IF	CITATIONS
19	What potential do aptamers hold in therapeutic delivery?. <i>Therapeutic Delivery</i> , 2017, 8, 53-55.	2.2	4
20	Development of a Bifunctional Aptamer Targeting the Transferrin Receptor and Epithelial Cell Adhesion Molecule (EpCAM) for the Treatment of Brain Cancer Metastases. <i>ACS Chemical Neuroscience</i> , 2017, 8, 777-784.	3.5	75
21	Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells. <i>Scientific Reports</i> , 2017, 7, 5898.	3.3	40
22	Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery. <i>Theranostics</i> , 2017, 7, 4071-4086.	10.0	70
23	Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2576.	4.1	31
24	Development of Cell-Specific Aptamers: Recent Advances and Insight into the Selection Procedures. <i>Molecules</i> , 2017, 22, 2070.	3.8	35
25	Truncation and Mutation of a Transferrin Receptor Aptamer Enhances Binding Affinity. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 348-354.	3.6	56
26	The Application of Aptamers for Immunohistochemistry. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 120-126.	3.6	22
27	Application of Aptamers in Histopathology. <i>Methods in Molecular Biology</i> , 2016, 1380, 191-196.	0.9	3
28	EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. <i>Theranostics</i> , 2015, 5, 1456-1472.	10.0	84
29	Aptamer-Mediated Cancer Gene Therapy. <i>Current Gene Therapy</i> , 2015, 15, 109-119.	2.0	18
30	Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors. <i>Theranostics</i> , 2015, 5, 1083-1097.	10.0	147
31	Fabrication of high specificity hollow mesoporous silica nanoparticles assisted by Eudragit for targeted drug delivery. <i>Journal of Colloid and Interface Science</i> , 2015, 445, 151-160.	9.4	59
32	Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles. <i>Nanoscale</i> , 2015, 7, 14080-14092.	5.6	68
33	The control of epidermal growth factor grafted on mesoporous silica nanoparticles for targeted delivery. <i>Journal of Materials Chemistry B</i> , 2015, 3, 6094-6104.	5.8	10
34	Ethosomes the Best Approach for Deeper Delivery of Drugs Through Transdermal Port: From Preparation to Biomedical Applications. <i>Journal of Colloid Science and Biotechnology</i> , 2015, 4, 87-98.	0.2	2
35	Cancer stem cell targeted therapy: progress amid controversies. <i>Oncotarget</i> , 2015, 6, 44191-44206.	1.8	129
36	Nucleic Acid Aptamer-Guided Cancer Therapeutics and Diagnostics: the Next Generation of Cancer Medicine. <i>Theranostics</i> , 2015, 5, 23-42.	10.0	184

#	ARTICLE	IF	CITATIONS
37	Cytokine Networks and Cancer Stem Cells. , 2015, , 67-87.		1
38	Improved Efficacy and Reduced Toxicity of Doxorubicin Encapsulated in Sulfatide-Containing Nanoliposome in a Glioma Model. PLoS ONE, 2014, 9, e103736.	2.5	16
39	CD44 variant 6 is associated with prostate cancer metastasis and chemo/radioresistance. Prostate, 2014, 74, 602-617.	2.3	126
40	Inflammation and cancer stem cells. Cancer Letters, 2014, 345, 271-278.	7.2	105
41	Cancer stem cells: A contentious hypothesis now moving forward. Cancer Letters, 2014, 344, 180-187.	7.2	217
42	Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells. International Journal of Nanomedicine, 2014, 9, 1083.	6.7	72
43	Epithelial cell adhesion molecule (EpcAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. International Journal of Biochemistry and Cell Biology, 2013, 45, 2736-2748.	2.8	155
44	RNA aptamers targeting cancer stem cell marker CD133. Cancer Letters, 2013, 330, 84-95.	7.2	157
45	Aptamers as Theranostic Agents: Modifications, Serum Stability and Functionalisation. Sensors, 2013, 13, 13624-13637.	3.8	104
46	The Use of Sensitive Chemical Antibodies for Diagnosis: Detection of Low Levels of Epcam in Breast Cancer. PLoS ONE, 2013, 8, e57613.	2.5	40
47	Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo. International Journal of Nanomedicine, 2013, 8, 4103.	6.7	155
48	Role of the EpCAM (CD326) in prostate cancer metastasis and progression. Cancer and Metastasis Reviews, 2012, 31, 779-791.	5.9	68
49	Cancer stem cell targeting: the next generation of cancer therapy and molecular imaging. Therapeutic Delivery, 2012, 3, 227-244.	2.2	32
50	Enhanced Antitumor Efficacy and Reduced Systemic Toxicity of Sulfatide-Containing Nanoliposomal Doxorubicin in a Xenograft Model of Colorectal Cancer. PLoS ONE, 2012, 7, e49277.	2.5	29
51	Groundwater pre-treatment prevents the onset of chronic ulcerative dermatopathy in juvenile Murray cod, <i>Maccullochella peelii peelii</i> (Mitchell). Aquaculture, 2011, 312, 19-25.	3.5	5
52	RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Science, 2011, 102, 991-998.	3.9	199
53	Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies. British Journal of Haematology, 2011, 155, 3-13.	2.5	30
54	Elevated Levels of Triglyceride and Triglyceride-Rich Lipoprotein Triglyceride Induced by a High-Carbohydrate Diet Is Associated with Polymorphisms of <i>APOA5</i> and <i>APOC3</i> in Chinese Healthy Young Adults. Annals of Nutrition and Metabolism, 2011, 58, 150-157.	1.9	12

#	ARTICLE	IF	CITATIONS
55	TaqIB polymorphism in the CETP gene modulates the impact of HC/LF diet on the HDL profile in healthy Chinese young adults. <i>Journal of Nutritional Biochemistry</i> , 2010, 21, 1114-1119.	4.2	14
56	Cytochemical characterisation of the leucocytes and thrombocytes from Murray cod (<i>Maccullochella peelii peelii</i> , Mitchell). <i>Fish and Shellfish Immunology</i> , 2009, 26, 731-736.	3.6	33
57	Functional interaction between mutations in the granulocyte colony-stimulating factor receptor in severe congenital neutropenia. <i>British Journal of Haematology</i> , 2008, 142, 653-656.	2.5	12
58	Blood cells of Murray cod <i>Maccullochella peelii peelii</i> (Mitchell). <i>Journal of Fish Biology</i> , 2007, 70, 973-980.	1.6	16
59	Cancer Stem Cells – Perspectives and How to Target Them. , 0, , .		0